Literature DB >> 31335392

Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.

Rabih Said1, Apostolia-Maria Tsimberidou.   

Abstract

Precision medicine incorporates information regarding tumor biology involved in patients' carcinogenesis and individualized treatment of patients using drugs that inhibit the molecular basis of their disease. Implementation of precision medicine accelerated the drug approval process, translating discoveries in basic science and biotechnology into patient care. Clinical trials with innovative or adaptive design including "basket" and "umbrella" trials explore personalized therapies against in selected tumor types and/or across tumor types. In 2007, we started the Initiative for Molecular Profiling and Advanced Cancer Therapy, the first precision medicine program across tumor types. We demonstrated that therapy matched to patients' tumor molecular profiling is associated with improved rates of response, progression-free survival, and overall survival compared with nonmatched targeted therapy. We have now entered a new era of precision medicine that includes comprehensive tumor testing and multiple innovative modalities hoping to overcome the complexity of tumor biology to improve patient outcomes.

Entities:  

Year:  2019        PMID: 31335392      PMCID: PMC6657521          DOI: 10.1097/PPO.0000000000000393

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  19 in total

1.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

2.  Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

Authors:  Apostolia-Maria Tsimberidou; Sijin Wen; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Kenneth Aldape; Yang Ye; Razelle Kurzrock; Donald Berry
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

3.  Lung cancer in the era of precision medicine.

Authors:  Katerina Politi; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

4.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Authors:  Filip Janku; David S Hong; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Gerald S Falchook; Apostolia M Tsimberidou; Vanda M Stepanek; Stacy L Moulder; J Jack Lee; Rajyalakshmi Luthra; Ralph G Zinner; Russell R Broaddus; Jennifer J Wheler; Razelle Kurzrock
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

5.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

7.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

8.  VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Authors:  Maria Schwaederlé; Vladimir Lazar; Pierre Validire; Johan Hansson; Ludovic Lacroix; Jean-Charles Soria; Yudi Pawitan; Razelle Kurzrock
Journal:  Cancer Res       Date:  2015-02-11       Impact factor: 12.701

9.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

10.  P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

Authors:  Rabin Said; David S Hong; Carla L Warneke; J Jack Lee; Jennifer J Wheler; Filip Janku; Aung Naing; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Oncotarget       Date:  2013-05
View more
  4 in total

Review 1.  Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.

Authors:  Dylan C Brock; Scott Demarest; Tim A Benke
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

2.  Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.

Authors:  Mohammad Faraz Naqvi; Henry Hiep Vo; David Vining; Apostolia-Maria Tsimberidou
Journal:  Ther Adv Med Oncol       Date:  2021-03-24       Impact factor: 8.168

3.  Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.

Authors:  Chi-Cheng Huang; Yi-Fang Tsai; Chun-Yu Liu; Ta-Chung Chao; Pei-Ju Lien; Yen-Shu Lin; Chin-Jung Feng; Jen-Hwey Chiu; Chih-Yi Hsu; Ling-Ming Tseng
Journal:  BMC Cancer       Date:  2021-02-25       Impact factor: 4.430

Review 4.  Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges.

Authors:  Qi Zhang; Qihan Fu; Xueli Bai; Tingbo Liang
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.